Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Regen BioPharma (RGBP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.

  • Regen BioPharma's Consolidated Net Income fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Dec 2025 it was -$759115.0, marking a year-over-year increase of 2691.72%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
  • Per Regen BioPharma's latest filing, its Consolidated Net Income stood at -$572469.0 for Q3 2025, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's Consolidated Net Income peaked at -$13047.0 during Q1 2021, and registered a low of -$572469.0 during Q3 2025.
  • For the 5-year period, Regen BioPharma's Consolidated Net Income averaged around -$182475.5, with its median value being -$128529.0 (2022).
  • Per our database at Business Quant, Regen BioPharma's Consolidated Net Income skyrocketed by 8924.9% in 2021 and then crashed by 81250.86% in 2022.
  • Over the past 5 years, Regen BioPharma's Consolidated Net Income (Quarter) stood at -$141432.0 in 2021, then plummeted by 240.25% to -$481226.0 in 2022, then skyrocketed by 69.88% to -$144932.0 in 2023, then tumbled by 255.6% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
  • Its last three reported values are -$572469.0 in Q3 2025, -$167292.0 for Q2 2025, and -$19354.0 during Q1 2025.